Skip to main content

IMerge Clinical Data in Patients With Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis-Stimulating Agents

FEATURING:

Guillermo Garcia-Manero, MD
Professor, Department of Leukemia, Division of Cancer Medicine
Chief, Section of Myelodysplastic Syndromes, Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Guillermo Garcia-Manero, MD, from MD Anderson Cancer Center, explores imetelstat trial results of patients with transfusion-dependent lower-risk myelodysplastic syndromes who experience failure to or are ineligible for treatment with erythropoiesis-stimulating agents.

Related Items